A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease

Bruce M Prenner, Stan Bukofzer, Sarah Behm, Kathleen Feaheny, Bruce E McNutt, Bruce M Prenner, Stan Bukofzer, Sarah Behm, Kathleen Feaheny, Bruce E McNutt

Abstract

Background: Adenosine receptor stress agents for myocardial perfusion imaging (MPI) may cause A(2B) and/or A(3) receptor-mediated bronchoconstriction, of particular concern to physicians testing patients with asthma or chronic obstructive pulmonary disease (COPD).

Methods: A Phase 4, randomized, double-blind study (NCT00862641) assessed the safety of the selective A(2A) receptor agonist, regadenoson, compared with placebo in subjects with asthma or COPD who represented likely candidates for MPI.

Results: Overall, 356 and 176 subjects with asthma and 316 and 151 subjects with COPD received regadenoson and placebo, respectively. The percentage of subjects experiencing a >15% decrease in FEV(1) from baseline to any assessment up to 24 hours post-baseline was not statistically significantly different between the regadenoson and the placebo groups in the asthma or COPD stratum. Dyspnea, the most frequent respiratory adverse event, occurred with higher incidence (P < .0001) in the regadenoson group than the placebo group in the asthma (10.7% vs 1.1%) and COPD (18.0% vs 2.6%) strata. No subjects experienced severe bronchoconstriction, although the occurrence of such reactions with adenosine receptor agonists cannot be ruled out, such that caution is advised.

Conclusions: This information may be helpful to physicians selecting a pharmacologic stress agent for MPI in patients with asthma or COPD.

Figures

Figure 1
Figure 1
Subject disposition flow diagrams for the asthma (A) and COPD (B) disease strata

References

    1. Henzlova MJ, Cerqueira MD, Taillefer R, Mahmarian JJ, Yao SS, Quality Assurance Committee of the American Society of Nuclear Cardiology. Stress protocols and tracers. J Nucl Cardiol 2009. doi:10.1007/s12350-009-9062-4.
    1. Belardinelli L, Shryock JC, Snowdy S, et al. The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther. 1998;284:1066–1073.
    1. Cerqueira MD. Advances in pharmacologic agents in imaging: New A2A receptor agonists. Curr Cardiol Rep. 2006;8:119–122. doi: 10.1007/s11886-006-0022-1.
    1. Gao Z, Li Z, Baker SP, et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther. 2001;298:209–218.
    1. Leaker BR, O’Connor B, Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial. J Nucl Cardiol. 2008;15:329–336. doi: 10.1016/j.nuclcard.2008.02.009.
    1. Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial) J Nucl Cardiol. 2008;15:319–328. doi: 10.1016/j.nuclcard.2008.02.013.
    1. Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. 2008. Updated May 2009. . Accessed March 7, 2012.
    1. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161:309–329.
    1. National Heart Lung and Blood Institute (NHLBI) Stepwise Approach for Managing Asthma in Youths ≥12 Years of Age and Adults. . Accessed March 7, 2012.
    1. Global initiative for chronic obstructive lung disease (GOLD) criteria. 2010. . Accessed March 7, 2012.
    1. Astellas Pharma US Inc. Regadenoson (Lexiscan) Prescribing Information (US). 2011. . Accessed March 7, 2012.
    1. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008;1:307–316. doi: 10.1016/j.jcmg.2008.02.003.
    1. Hendel RC, Bateman TM, Cerqueira MD, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005;46:2069–2075. doi: 10.1016/j.jacc.2005.05.097.
    1. Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14:645–658. doi: 10.1016/j.nuclcard.2007.06.114.
    1. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol. 1994;23:384–389. doi: 10.1016/0735-1097(94)90424-3.
    1. Lette J, Tatum JL, Fraser S, et al. Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study. J Nucl Cardiol. 1995;2:3–17. doi: 10.1016/S1071-3581(05)80003-0.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다